A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo

56Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The hypoxic cell radiosensitizing properties of nimorazole have been investigated in a C3H mammary carcinoma transplanted to the feet of C3D2F1. The results have been compared with those obtained with misonidazole (MISO) in the same animal tumour system. For single-dose irradiation in air, nimorazole gives an enhancement ratio (ER) of ˜ 1.4, independent of the dose of drug administered over the range 0.1-1.0 mg/g. MISO yields a similar ER at the 0.1 mg/g level but, unlike nimorazole, shows a steep dose-response curve with an ER of 2.2 when given in a concentration of 1.0 mg/g. No such dose-response relationship is seen with nimorazole despite the fact that tumour and plasma concentrations of the 2 drugs have an identical dose relationship. With irradiation given in 5 daily fractions, nimorazole and MISO at a dose of 0.3 mg/g per fraction both show an ER of ˜ 1.3. The high drug doses used in single-fraction radiation experiments in animals bear little relation to those applicable to clinical practice since these would result in unacceptable toxicity. The results of the present studies are therefore of interest as nimorazole is potentially less toxic than MISO in humans but demonstrates similar radiosensitizing properties at clinically relevant dose levels. © 1982 Cancer Research Campaign. All rights reserved.

References Powered by Scopus

Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo

307Citations
N/AReaders
Get full text

Structure-activity relationships in the development of hypoxic cell radiosensitizers: I. Sensitization efficiency

188Citations
N/AReaders
Get full text

Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole

172Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

534Citations
N/AReaders
Get full text

Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers

390Citations
N/AReaders
Get full text

Clinical Pharmacokinetics of Metronidazole and Other Nitroimidazole Anti-Infectives

189Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Overgaard, J., Overgaard, M., Nielsen, O. S., Pedersen, A. K., & Timothy, A. R. (1982). A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. British Journal of Cancer, 46(6), 904–911. https://doi.org/10.1038/bjc.1982.300

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

55%

Researcher 4

36%

Professor / Associate Prof. 1

9%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 5

45%

Agricultural and Biological Sciences 3

27%

Medicine and Dentistry 2

18%

Chemistry 1

9%

Save time finding and organizing research with Mendeley

Sign up for free